NASDAQ:ACRV Acrivon Therapeutics Q2 2025 Earnings Report $2.13 +0.07 (+3.40%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Acrivon Therapeutics EPS ResultsActual EPS-$0.55Consensus EPS -$0.57Beat/MissBeat by +$0.02One Year Ago EPSN/AAcrivon Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAcrivon Therapeutics Announcement DetailsQuarterQ2 2025Date8/13/2025TimeBefore Market OpensConference Call DateWednesday, August 13, 2025Conference Call Time4:00PM ETUpcoming EarningsAcrivon Therapeutics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Acrivon Therapeutics Earnings HeadlinesAcrivon Therapeutics to Present at the 2026 Cantor Global Healthcare ConferenceSeptember 2 at 8:00 AM | globenewswire.comAcrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business OfficerAugust 31, 2026 | globenewswire.comThe ultimate IPO unicorn before Labor DayAnthropic is now valued at over $1 trillion, more than every U.S. airline combined and larger than the U.S. defense budget. Its annualized revenue grew 80x in the first quarter, and an IPO could arrive as early as October. For a limited time, investors can access a report detailing how to explore a pre-IPO stake in Anthropic for $29, a 94% discount off the retail price. The package includes a year of Disruptors and Dominators, monthly stock ideas, and four special reports.September 4 at 1:00 AM | Weiss Ratings (Ad)Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data CatalystsAugust 13, 2026 | finance.yahoo.comAcrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 StudyAugust 5, 2026 | globenewswire.comAcrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 ConferenceJuly 21, 2026 | globenewswire.comSee More Acrivon Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Acrivon Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Acrivon Therapeutics and other key companies, straight to your email. Email Address About Acrivon TherapeuticsAcrivon Therapeutics (NASDAQ:ACRV) (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics. The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials. In parallel, Acrivon is advancing additional stapled-peptide programs directed at other oncogenic KRAS mutants such as G12D, with the goal of expanding its pipeline to address multiple unmet needs in solid tumor oncology. Acrivon was established in 2021 as a spin-out from Calibr, the drug discovery division of The Scripps Research Institute, and is headquartered in Redwood City, California. The company leverages its origin in academic research to maintain close collaborations with leading cancer centers and translational science groups across North America and Europe. Supported by a management team with extensive experience in biotechnology and pharmaceutical drug development, Acrivon is building strategic partnerships and advancing its peptide platform to potentially deliver first-in-class or best-in-class therapies for patients with RAS-mutant cancers. The company continues to focus on rigorous clinical development and regulatory engagement to bring novel peptide-based oncology treatments to market.View Acrivon Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Snowflake’s AI Momentum Is Forcing a Fresh Look at the StockAeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityFB Financial's Southern Expansion and Buybacks Drive Analyst OptimismRetail Earnings Just Exposed a Bigger Divide in the U.S. Consumer EconomyAccelerant’s Take-Private Deal Raises a Bigger Question for Insurance StocksDefense Stocks Are Pulling Back as Their Navy Tailwinds Get StrongerThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story Upcoming Earnings Adobe (9/10/2026)Oracle (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
